^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RBS2418

    i
    Other names: RBS2418
    Associations

    News

    Trials
    Company:
    Riboscience
    Drug class:
    ENPP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Phase 2a, Randomized, Open-Label Study of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=220, Not yet recruiting, Riboscience, LLC.
    New P2 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • RBS2418
    5ms
    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=164, Recruiting, Riboscience, LLC. | N=64 --> 164 | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Sep 2025 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • RBS2418
    10ms
    VISTA-1: Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Riboscience, LLC.
    New P2 trial
    |
    RBS2418
    over1year
    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=64, Recruiting, Riboscience, LLC. | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • RBS2418
    over1year
    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=64, Recruiting, Riboscience, LLC. | Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • RBS2418
    2years
    RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors (clinicaltrials.gov)
    P1, N=64, Recruiting, Riboscience, LLC. | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • RBS2418
    over2years
    Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors (ESMO 2023)
    The PK profile showed plasma levels enabling complete ENPP1 inhibition. Preliminary analyses support the hypothesis that ENPP1 and cGAS co-expression in tumors correlates with RBS2418 treatment associated immune activation and prolonged disease stabilization suggestive of clinical benefit in multiple patients with refractory malignancies including MSS CRC and HCC (NCT05270213).
    Clinical • PK/PD data • Combination therapy • PD(L)-1 Biomarker • Immunomodulating
    |
    CGAS (Cyclic GMP-AMP Synthase)
    |
    Keytruda (pembrolizumab) • RBS2418